Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13304117 | 0.79 | BLM (0.39) | NPSR1ACHE | |
| SCHEMBL27534706 | 0.75 | FDPS (0.51) | FDPSCYP2C19CYP1A2CYP2C9KMT2A | |
| SCHEMBL13304136 | 0.74 | TSHR (0.47) | CYP2C19CYP1A2CYP2C9KMT2ASMN1; SMN2 | |
| SCHEMBL15004032 | 0.74 | PPARG (0.54) | FDPSCYP2C19CYP1A2CYP2C9KMT2A | |
| SCHEMBL4867129 | 0.73 | FDPS (0.48) | FDPSCYP2C19CYP1A2CYP2C9KMT2A | |
| SCHEMBL2844383 | 0.72 | KDM4E (0.34) | NPSR1ALDH1A1ACHELMNACYP3A4 | |
| SCHEMBL4284433 | 0.71 | ESR1 (0.44) | CYP2C19CYP1A2CYP2C9NPSR1ALDH1A1 | |
| SCHEMBL9676215 | 0.70 | TSHR (0.52) | NPSR1ACHELMNACYP3A4 | |
| SCHEMBL4278598 | 0.70 | ADRB2 (0.40) | CYP2C19CYP1A2CYP2C9NPSR1CYP3A4 | |
| SCHEMBL5414824 | 0.69 | CYP1A2 (0.57) | CYP2C19CYP1A2CYP2C9KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | PDE3A, PDE3B, PDE2A | FDPS 1463/4885CYP2C19 88/4885CYP1A2 80/4885 |
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | PDE3A, PDE5A, PDE2A | FDPS 1164/4885CYP2C19 88/4885CYP1A2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.